Chinese cancer drugs are bringing affordable relief to Indian patients as hospitals and pharmaceutical companies increasingly introduce lower-cost immunotherapy medicines into the country.
The development is helping thousands of cancer patients in India access advanced treatment options that were previously too expensive for many families. Doctors say the arrival of these medicines is gradually changing the way cancer care in India is delivered, especially for middle-class and lower-income patients who often struggle with rising treatment costs.
Many of these medicines are entering the Indian market through partnerships between Indian pharmaceutical companies and Chinese biotech firms. These collaborations are helping reduce the cost of immunotherapy treatment that was earlier dominated by expensive Western drugs.
According to oncologists, some imported therapies can cost between ?2 lakh and ?5 lakh per treatment cycle, while affordable cancer medicines from Chinese companies are available at a much lower price, making long-term treatment more manageable for patients.
Doctors at major hospitals say patients are already seeing positive results. At Mumbai’s PD Hinduja Hospital, a 72-year-old lung cancer patient reportedly responded well to a Chinese-origin immunotherapy drug after high treatment costs made other options difficult. Specialists noted visible improvement after a few cycles, highlighting how lung cancer treatment is becoming more accessible through lower-cost medicines.
Also Read: Biocon Eyes Capital Utilisation and Profitability Growth
Healthcare experts believe this shift is especially important in India, where cancer treatment costs often force families into debt. Since a large part of healthcare spending in the country comes directly from patients’ pockets, affordable medicines are becoming increasingly important in improving access to care. Oncologists say lower-cost therapies can help more patients complete treatment instead of stopping midway because of financial challenges linked to advanced cancer treatment expenses.
Several Indian pharmaceutical companies, including Intas Pharmaceuticals, Glenmark Pharmaceuticals, and Dr. Reddy’s Laboratories, have partnered with Chinese firms to launch cancer medicines for diseases such as lung cancer, oesophageal cancer, and nasopharyngeal carcinoma. These collaborations are also helping expand the availability of oncology drugs in India and modern treatment options across the country.
Doctors say concerns around the quality of Chinese medicines have reduced over time as patient outcomes continue to improve. Experts believe the growing partnership between Indian and Chinese pharmaceutical companies could play a major role in strengthening affordable healthcare in India and making advanced cancer treatment more accessible in the years ahead.
.jpg)
.jpg)
